Bartels, Claudia

[["dc.bibliographiccitation.firstpage","92"],["dc.bibliographiccitation.issue","2"],["dc.bibliographiccitation.journal","Alcohol and Alcoholism"],["dc.bibliographiccitation.lastpage","102"],["dc.bibliographiccitation.volume","42"],["dc.contributor.author","Bartels, Claudia"],["dc.contributor.author","Kunert, Hanns-Jürgen"],["dc.contributor.author","Stawicki, Sabina"],["dc.contributor.author","Kröner-Herwig, Birgit"],["dc.contributor.author","Ehrenreich, Hannelore"],["dc.contributor.author","Krampe, Henning"],["dc.date.accessioned","2017-09-07T11:46:30Z"],["dc.date.available","2017-09-07T11:46:30Z"],["dc.date.issued","2007"],["dc.description.abstract","The hippocampus (HC) is characterized by high vulnerability to noxious influence, but also by a considerable regenerative potential. Although deficits in HC-related functions are among the most commonly reported cognitive sequelae in alcoholism, little and conflicting information is available concerning regeneration upon abstinence. The present study has been designed to evaluate (i) the frequency of measurable dysfunction in so called HC tests and (ii) its predictive value for risk to relapse in a cohort of 50 severely affected chronic alcoholic patients and (iii) to monitor recovery of HC-related functions upon strict abstention from alcohol. Patients underwent a 2-year neuropsychological follow-up including HC-associated tests (Verbal Learning Test, VLT; Nonverbal Learning Test, NVLT; 'City Map Test' of Learning and Memory Test, LGT-3), as well as tests of intelligence and attention in the framework of OLITA (Outpatient Long-Term Intensive Therapy for Alcoholics), a programme with careful abstinence monitoring. At study entry, 30/50 (60%) alcoholics had HC dysfunction which tended to predict a lower long-term abstinence probability (P = 0.058). Of the subgroup that could be followed under conditions of strictly monitored alcohol abstinence (n = 32; age 44.7 +/- 6.2 years; 23 men, 9 women), 53% (17/32) exhibited distinct HC dysfunction at inclusion which returned to normal after 2 years. Patients with initially normal HC function (9/32) and patients with additional brain damage of different aetiologies (6/32) failed to show improvement on HC-related tests. While the former displayed stably normal HC test performance, the latter remained on a performance level below normal. Demonstrating slow but remarkable regeneration of HC functions upon strict abstention from alcohol, our data strongly support abstinence-oriented long-term treatment of alcoholics. The absence of functional recovery in patients with additional causes of brain damage might be explained by the 'dual hit' exhausting the regenerative potential of the HC."],["dc.identifier.doi","10.1093/alcalc/agl104"],["dc.identifier.gro","3150510"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/7282"],["dc.language.iso","en"],["dc.notes.status","final"],["dc.relation.issn","0735-0414"],["dc.title","Recovery of hippocampus-related functions in chronic alcoholics during monitored long-term abstinence"],["dc.type","journal_article"],["dc.type.internalPublication","unknown"],["dc.type.peerReviewed","no"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","e647"],["dc.bibliographiccitation.issue","12"],["dc.bibliographiccitation.journal","Stroke"],["dc.bibliographiccitation.lastpage","e656"],["dc.bibliographiccitation.volume","40"],["dc.contributor.author","Ehrenreich, Hannelore"],["dc.contributor.author","Weißenborn, Karin"],["dc.contributor.author","Prange, Hilmar"],["dc.contributor.author","Schneider, Dietmar"],["dc.contributor.author","Weimar, Christian"],["dc.contributor.author","Wartenberg, Katja"],["dc.contributor.author","Schellinger, Peter D."],["dc.contributor.author","Bohn, Matthias"],["dc.contributor.author","Becker, Harald"],["dc.contributor.author","Wegrzyn, Martin"],["dc.contributor.author","Jähnig, Peter"],["dc.contributor.author","Herrmann, Manfred"],["dc.contributor.author","Knauth, Michael"],["dc.contributor.author","Bähr, Mathias"],["dc.contributor.author","Heide, Wolfgang"],["dc.contributor.author","Wagner, Armin"],["dc.contributor.author","Schwab, Stefan"],["dc.contributor.author","Reichmann, Heinz"],["dc.contributor.author","Schwendemann, Günther"],["dc.contributor.author","Dengler, Reinhard"],["dc.contributor.author","Kastrup, Andreas"],["dc.contributor.author","Bartels, Claudia"],["dc.date.accessioned","2017-09-07T11:46:20Z"],["dc.date.available","2017-09-07T11:46:20Z"],["dc.date.issued","2009-12"],["dc.description.abstract","Background and Purpose— Numerous preclinical findings and a clinical pilot study suggest that recombinant human erythropoietin (EPO) provides neuroprotection that may be beneficial for the treatment of patients with ischemic stroke. Although EPO has been considered to be a safe and well-tolerated drug over 2 decades, recent studies have identified increased thromboembolic complications and/or mortality risks on EPO administration to patients with cancer or chronic kidney disease. Accordingly, the double-blind, placebo-controlled, randomized German Multicenter EPO Stroke Trial (Phase II/III; ClinicalTrials.gov Identifier: NCT00604630) was designed to evaluate efficacy and safety of EPO in stroke.Methods— This clinical trial enrolled 522 patients with acute ischemic stroke in the middle cerebral artery territory (intent-to-treat population) with 460 patients treated as planned (per-protocol population). Within 6 hours of symptom onset, at 24 and 48 hours, EPO was infused intravenously (40 000 IU each). Systemic thrombolysis with recombinant tissue plasminogen activator was allowed and stratified for.Results— Unexpectedly, a very high number of patients received recombinant tissue plasminogen activator (63.4%). On analysis of total intent-to-treat and per-protocol populations, neither primary outcome Barthel Index on Day 90 (P=0.45) nor any of the other outcome parameters showed favorable effects of EPO. There was an overall death rate of 16.4% (n=42 of 256) in the EPO and 9.0% (n=24 of 266) in the placebo group (OR, 1.98; 95% CI, 1.16 to 3.38; P=0.01) without any particular mechanism of death unexpected after stroke.Conclusions— Based on analysis of total intent-to-treat and per-protocol populations only, this is a negative trial that also raises safety concerns, particularly in patients receiving systemic thrombolysis."],["dc.identifier.doi","10.1161/STROKEAHA.109.564872"],["dc.identifier.gro","3150483"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/7252"],["dc.language.iso","en"],["dc.notes.status","final"],["dc.subject","clinical trial; hematopoietic growth factor; neuroprotection; NIHSS; rtPA"],["dc.title","Recombinant Human Erythropoietin in the Treatment of Acute Ischemic Stroke"],["dc.type","journal_article"],["dc.type.internalPublication","unknown"],["dc.type.peerReviewed","no"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.journal","Multiple Sclerosis Journal"],["dc.contributor.author","Bartels, Claudia"],["dc.contributor.author","Ehrenreich, Hannelore"],["dc.date.accessioned","2018-03-08T09:22:14Z"],["dc.date.available","2018-03-08T09:22:14Z"],["dc.date.issued","2017"],["dc.identifier.doi","10.1177/1352458517733132"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/12915"],["dc.language.iso","en"],["dc.notes.intern","GRO-Li-Import"],["dc.notes.status","final"],["dc.relation.doi","10.1177/1352458517733132"],["dc.relation.issn","1352-4585"],["dc.relation.issn","1477-0970"],["dc.title","How to pursue EPO in MS"],["dc.type","journal_article"],["dc.type.internalPublication","unknown"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","86"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","Alcoholism: Clinical and Experimental Research"],["dc.bibliographiccitation.lastpage","95"],["dc.contributor.author","Krampe, Henning"],["dc.contributor.author","Stawicki, Sabina"],["dc.contributor.author","Wagner, Thilo"],["dc.contributor.author","Bartels, Claudia"],["dc.contributor.author","Aust, Carlotta"],["dc.contributor.author","Rüther, Eckart"],["dc.contributor.author","Poser, Wolfgang"],["dc.contributor.author","Ehrenreich, Hannelore"],["dc.date.accessioned","2017-09-07T11:46:33Z"],["dc.date.available","2017-09-07T11:46:33Z"],["dc.date.issued","2006"],["dc.description.abstract","Objective: (1) To perform a 9-year study of abstinence, lapse, and relapse in 180 chronic alcoholic patients, participants of the Outpatient Longterm Intensive Therapy for Alcoholics (OLITA); (2) To investigate the role of supervised alcohol deterrents (AD) in relapse prevention and as an adjunct for maintenance of long-term abstinence. Method: This prospective open treatment study evaluates the long-term course of drinking outcomes and AD use of 180 chronic alcoholics consecutively admitted from 1993 to 2002. Subsamples are compared for (1) sham-AD versus verum-AD (disulfiram/calcium carbimide), (2) coped lapses versus finally detrimental lapses versus malignant relapses, and (3) AD use for 13 to 20 versus {.extbackslash}textgreater 20 months. Results: In this 9-year study, the cumulative probability of not having relapsed was 0.52, and that of not having consumed any alcohol was 0.26. Despite long-term use, disulfiram/calcium carbimide was well tolerated. Patients on sham-AD (due to contraindications to verum-AD) showed higher cumulative abstinence probability than patients on verum (S {.extbackslash}textequals 0.86 vs. S {.extbackslash}textequals 0.49, p {.extbackslash}textequals 0.03). Detrimental lapses and malignant relapses occurred earlier than successfully coped lapses (p {.extbackslash}textless 0.001); patients with detrimental lapse and with malignant relapse had rewer days of AD intake and less subsequent days without AD than patients with coped lapse (p {.extbackslash}textless 0.001). The cumulative abstinence probability was S {.extbackslash}textequals 0.75 for patients with long-term intake compared with S {.extbackslash}textequals 0.50 for patients who stopped AD between months 13 and 20 (p {.extbackslash}textless 0.001). Conclusions: An abstinence rate of {.extbackslash}textgreater 50{.extbackslash}textpercent in this 9-year study strongly supports the concept of comprehensive, long-term outpatient treatment of alcoholics. Supervised, guided intake of AD, also over extended periods, can be used as a predominantly psychologically acting ingredient of successful alcoholism therapy."],["dc.identifier.doi","10.1111/j.1530-0277.2006.00013.x"],["dc.identifier.gro","3150523"],["dc.identifier.pmid","16433735"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/7295"],["dc.language.iso","en"],["dc.notes.status","zu prüfen"],["dc.relation.issn","0145-6008"],["dc.title","Follow-up of 180 alcoholic patients for up to 7 years after outpatient treatment: Impact of alcohol deterrents on outcome"],["dc.type","journal_article"],["dc.type.internalPublication","unknown"],["dc.type.peerReviewed","yes"],["dspace.entity.type","Publication"]]

[["dc.contributor.author","Ehrenreich, Hannelore"],["dc.contributor.author","Bartels, Claudia"],["dc.contributor.editor","Nowrousian, Mohammad Resa"],["dc.date.accessioned","2017-09-07T11:45:47Z"],["dc.date.available","2017-09-07T11:45:47Z"],["dc.date.issued","2008"],["dc.description.abstract","Western industrialized countries have to deal with ever increasing numbers of patients suffering from diseases of the nervous system. This growing problem poses a growing challenge for novel medical strategies and is based on an increasingly aging population due to considerable improvements in general health care/treatment outcome as well as alterations in lifestyle. The prototype of an acute brain disease, stroke, constitutes together with cardiovascular diseases, the second leading cause of death after cancer in industrialized nations. Among the prototype chronic disorders of the brain is Alzheimer’s disease with its dramatically increasing prevalence due to the increased life expectancy of the population (Ferri et al. 2005)."],["dc.identifier.gro","3150444"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/7209"],["dc.language.iso","en"],["dc.notes.status","final"],["dc.notes.submitter","chake"],["dc.publisher","Springer"],["dc.publisher.place","Wien, New York"],["dc.relation.ispartof","Recombinant human erythropoietin (rhEPO) in clinical oncology: Scientific and Clinical Aspects of Anemia in Cancer"],["dc.title","From bench to bedside : Neuroprotectiv effects of erythropoietin"],["dc.type","book_chapter"],["dc.type.internalPublication","unknown"],["dc.type.peerReviewed","no"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","108"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","Neurotherapeutics"],["dc.bibliographiccitation.lastpage","127"],["dc.bibliographiccitation.volume","6"],["dc.contributor.author","Sirén, Anna-Leena"],["dc.contributor.author","Faßhauer, Theresa"],["dc.contributor.author","Bartels, Claudia"],["dc.contributor.author","Ehrenreich, Hannelore"],["dc.date.accessioned","2017-09-07T11:45:45Z"],["dc.date.available","2017-09-07T11:45:45Z"],["dc.date.issued","2009"],["dc.description.abstract","The growth factor erythropoietin (EPO) and erythropoietin receptors (EPOR) are expressed in the nervous system. Neuronal expression of EPO and EPOR peaks during brain development and is upregulated in the adult brain after injury. Peripherally administered EPO, and at least some of its variants, cross the blood-brain barrier, stimulate neurogenesis, neuronal differentiation, and activate brain neurotrophic, anti-apoptotic, anti-oxidant and anti-inflammatory signaling. These mechanisms underlie their tissue protective effects in nervous system disorders. As the tissue protective functions of EPO can be separated from its stimulatory action on hematopoiesis, novel EPO derivatives and mimetics, such as asialo-EPO and carbamoylated EPO have been developed. While the therapeutic potential of the novel EPO derivatives continues to be characterized in preclinical studies, the experimental findings in support for the use of recombinant human (rh)EPO in human brain disease have already been translated to clinical studies in acute ischemic stroke, chronic schizophrenia, and chronic progressive multiple sclerosis. In this review article, we assess the studies on EPO and, in particular, on its structural or functional variants in experimental models of nervous system disorders, and we provide a short overview of the completed and ongoing clinical studies testing EPO as neuroprotective/neuroregenerative treatment option in neuropsychiatric disease."],["dc.identifier.doi","10.1016/j.nurt.2008.10.041"],["dc.identifier.gro","3150447"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/7212"],["dc.language.iso","en"],["dc.notes.status","final"],["dc.subject","Ischemia; cognition; motor function; hematocrit; thrombocytes; safety"],["dc.title","Therapeutic potential of erythropoietin and its structural or functional variants in the nervous system"],["dc.type","journal_article"],["dc.type.internalPublication","unknown"],["dc.type.peerReviewed","unknown"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","146"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","Journal of Renal Nutrition"],["dc.bibliographiccitation.lastpage","153"],["dc.bibliographiccitation.volume","18"],["dc.contributor.author","Ehrenreich, Hannelore"],["dc.contributor.author","Bartels, Claudia"],["dc.contributor.author","Sargin, Derya"],["dc.contributor.author","Stawicki, Sabina"],["dc.contributor.author","Krampe, Henning"],["dc.date.accessioned","2017-09-07T11:46:29Z"],["dc.date.available","2017-09-07T11:46:29Z"],["dc.date.issued","2008"],["dc.description.abstract","Treatment of human brain disease with erythropoietin (EPO) in order to achieve neuroprotection and/or neuroregeneration represents a totally new frontier in translational neuroscience. Rather than specifically targeting the cause of a particular disease entity, EPO nonspecifically influences components of the “final common pathway” that determine disease severity and progression in a number of entirely different brain diseases. EPO acts in an antiapoptotic, anti-inflammatory, antioxidant, neurotrophic, angiogenetic, stem cell–modulatory fashion. Importantly, it appears to influence neural plasticity. Most likely due to these properties, EPO has been found by many investigators to be protective or regenerative and to improve cognitive performance in various rodent models of neurological and psychiatric disease. The “Göttingen-EPO-stroke trial” has provided first promising data on humans for a neuroprotective therapy of an acute brain disease. Experimental EPO treatment to improve cognitive function in patients with schizophrenia represents a novel neuroregenerative strategy for a chronic brain disease. An exploratory trial in chronic progressive multiple sclerosis as an example of an inflammatory disease of the nervous system yielded first positive results of EPO treatment on both motor function and cognition. These promising results are just the beginning and will hopefully stimulate further work along these lines."],["dc.identifier.doi","10.1053/j.jrn.2007.10.029"],["dc.identifier.gro","3150511"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/7283"],["dc.language.iso","en"],["dc.notes.status","final"],["dc.title","Recombinant human erythropoietin in the treatment of human brain disease: focus on cognition"],["dc.type","journal_article"],["dc.type.internalPublication","unknown"],["dc.type.peerReviewed","unknown"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","708"],["dc.bibliographiccitation.issue","5"],["dc.bibliographiccitation.journal","Psychiatric Services"],["dc.bibliographiccitation.lastpage","712"],["dc.bibliographiccitation.volume","57"],["dc.contributor.author","Krampe, Henning"],["dc.contributor.author","Wagner, Thilo"],["dc.contributor.author","Stawicki, Sabina"],["dc.contributor.author","Bartels, Claudia"],["dc.contributor.author","Aust, Carlotta"],["dc.contributor.author","Kroener-Herwig, Birgit"],["dc.contributor.author","Kuefner, Heinrich"],["dc.contributor.author","Ehrenreich, Hannelore"],["dc.date.accessioned","2021-06-01T10:47:52Z"],["dc.date.available","2021-06-01T10:47:52Z"],["dc.date.issued","2006"],["dc.description.abstract","Objective: A prospective four-year study examined which components of addiction severity predicted time to relapse among 112 adults with chronic alcoholism who participated in a comprehensive outpatient treatment program. Methods: Recruited from emergency, inpatient, and outpatient facilities, patients were admitted into the program consecutively between March 1998 and June 2002. Alcohol abstinence was carefully monitored for four years from admission by regular contacts and urine and blood analyses. Alcoholism characteristics and personality disorders were assessed with structured interviews and the International Diagnostic Checklists for Personality Disorders. Results: Among a variety of potential variables, only presence of a personality disorder and chronicity of addiction were independently associated with a decrease of cumulative four-year abstinence probability. Conclusions: Their high predictive values suggest that chronicity and personality disorder rank among the most important characteristics of addiction severity."],["dc.identifier.doi","10.1176/ps.2006.57.5.708"],["dc.identifier.gro","3150525"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/85746"],["dc.language.iso","en"],["dc.notes.intern","DOI-Import GROB-425"],["dc.notes.status","final"],["dc.relation.eissn","1557-9700"],["dc.relation.issn","1075-2730"],["dc.subject","addiction severity; relapse; alcoholism treatment; personality disorder; prediction; addiction chronicity; 2006; Alcohol Rehabilitation; Alcoholism; Personality Disorders; Relapse (Disorders); Severity (Disorders); Chronicity (Disorders)"],["dc.title","Personality Disorder and Chronicity of Addiction as Independent OutcomePredictors in Alcoholism Treatment"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","no"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","e167"],["dc.bibliographiccitation.issue","3"],["dc.bibliographiccitation.journal","Stroke"],["dc.bibliographiccitation.lastpage","e168"],["dc.bibliographiccitation.volume","41"],["dc.contributor.author","Ehrenreich, Hannelore"],["dc.contributor.author","Bartels, Claudia"],["dc.contributor.author","Weißenborn, Karin"],["dc.contributor.author","Diener, Hans-Christoph"],["dc.date.accessioned","2017-09-07T11:45:46Z"],["dc.date.available","2017-09-07T11:45:46Z"],["dc.date.issued","2010"],["dc.description.abstract","In his letter, Christof Dame1 builds on and supports the points made in the discussion part of our recent erythropoietin (EPO) stroke article.2 Especially the exploratory analysis presented in this article, showing potential beneficial effects of EPO treatment in patients nonqualifying for recombinant tissue plasminogen activator (rtPA),2,3⇓ should definitely stimulate further basic research to better understand and define potential contraindications to EPO treatment for future EPO stroke trials. For this purpose, we decided to share with your readers a new set of data obtained during our extensive post hoc evaluation of the study that might give additional insight into the risk profile of EPO treatment."],["dc.identifier.doi","10.1161/STROKEAHA.109.575951"],["dc.identifier.gro","3150449"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/7214"],["dc.language.iso","en"],["dc.notes.status","final"],["dc.title","Response to Letter by Dame"],["dc.type","journal_article"],["dc.type.internalPublication","unknown"],["dc.type.peerReviewed","no"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.issue","5"],["dc.bibliographiccitation.journal","Pharmacopsychiatry"],["dc.bibliographiccitation.volume","40"],["dc.contributor.author","Krampe, Henning"],["dc.contributor.author","Stawicki, Sabina"],["dc.contributor.author","Niehaus, S."],["dc.contributor.author","Ribbe, K."],["dc.contributor.author","Wagner, T."],["dc.contributor.author","Bartels, C."],["dc.contributor.author","Kroener-Herwig, Birgit"],["dc.contributor.author","Ehrenreich, Hannelore"],["dc.date.accessioned","2018-11-07T10:59:23Z"],["dc.date.available","2018-11-07T10:59:23Z"],["dc.date.issued","2007"],["dc.format.extent","235"],["dc.identifier.isi","000249873600151"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/50685"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Georg Thieme Verlag Kg"],["dc.publisher.place","Stuttgart"],["dc.relation.conference","25th Symposium of the Arbeitsgemeinschaft-Neuropsychopharmakologie-und-Pharmakopsychiatrie"],["dc.relation.eventlocation","Munich, GERMANY"],["dc.relation.issn","0176-3679"],["dc.title","Prediction of outcome by multimodal monitoring of treatment processes in alcoholism therapy"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]